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Inﬂammation underlies the development and progression of a number of skin disorders including
psoriasis, atopic dermatitis and cancer. Therefore, novel antiinﬂammatory agents are of great clinical
interest for prevention and treatment of these conditions. Herein, we demonstrated the underlying
molecular mechanisms of the antiinﬂammatory activity of euphol, a tetracyclic triterpene isolated from
the sap of Euphorbia tirucalli, in skin inﬂammation induced by 12-O-tetradecanoylphorbol-13-acetate
(TPA) in mice. Topical application of euphol (100 mg/ear) signiﬁcantly inhibited TPA-induced ear edema
and leukocyte inﬂux through the reduction of keratinocyte-derived chemokine (CXCL1/KC) and
macrophage inﬂammatory protein (MIP)-2 levels. At the intracellular level, euphol reduced TPA-
induced extracellular signal-regulated protein kinase (ERK) activation and cyclooxygenase-2 (COX-2)
upregulation. These effects were associated with euphol’s ability to prevent TPA-induced protein kinase
C (PKC) activation, namely PKCa and PKCd isozymes. Our data indicate that topical application of
euphol markedly inhibits the inﬂammatory response induced by TPA. Thus, euphol represents a
promising agent for the management of skin diseases with an inﬂammatory component.
& 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
The skin is the primary interface between the body and the
environment, therefore, it is a major target for injury by a wide
spectrum of physical, chemical and microbial agents that are capable
of changing its structure and function (Bickers and Athar, 2006).
These insults are usually translated into inﬂammation, a reaction
required for successful cutaneous immune surveillance (Robert and
Kupper, 1999). Although protective, inﬂammation may be associated
with a number of skin disorders including psoriasis, atopic dermatitis,
and cancer (Johnson-Huang et al., 2009; Mueller, 2006). The inﬂam-
matory process is characterized by the release of a number of
mediators, including cytokines, chemotactic molecules, prostaglan-
dins, and vasoactive peptides, which culminates in changes in
vascular permeability and cellular inﬁltration (Levy, 1996). Extensive
experimental evidence has shown that exposure of skin to 12-O-
tetradecanoylphorbol-13-acetate (TPA) induces a pleiotrophic tissue
response encompassing a strong inﬂammatory reaction similar to
that observed in several skin diseases, and is one of the most potent
and frequently used tumor promoters (Hvid et al., 2008; Verma et al.,gia, Universidade Federal de
co D, CCB, Caixa Postal 476,
3@terra.com.br (J.B. Calixto).
ier OA license. 2006). TPA stimulates the activation of a wide variety of intracellular
pathways through the activation of protein kinase C (PKC), including
mitogen-activated protein kinases (MAPKs) and nuclear factor-kB
(NF-kB), as well as the generation of mediators like tumor necrosis
factor (TNF)-a, interleukin (IL)-1b, keratinocyte-derived chemokine
(CXCL1/KC), macrophage inﬂammatory protein (MIP)-2, and prosta-
glandins, among others (Cataisson et al., 2005,2006; Medeiros et al.,
2007; Otuki et al., 2005).
Euphorbia tirucalli L. (Euphorbiaceae), commonly known as aveloz
or pencil tree, is a subtropical and tropical ornamental plant, which is
used in folk medicine for the treatment of several kinds of cancer,
including basal cell carcinomas, leukemia, prostate and breast cancers
(De Melo et al., 2011; Valadares et al., 2006). It has been demon-
strated that the ethanolic extract of E. tirucalli signiﬁcantly increases
survival and reduces tumor growth in the peritoneal cavity of mice in
the Ehrlich ascites carcinoma model (Valadares et al., 2006). One of
the main constituents of the latex extracted from the plant is the
tetracyclic triterpene euphol. Euphol isolated from the roots of
Euphorbia kansui was shown to inhibit TPA-induced ear edema, as
well as tumor-promotion in the two-stage carcinogenesis induced by
7,12-dimethylbenz[a]anthracene (DMBA)-TPA protocol in mouse skin
(Yasukawa et al., 2000). However, the mechanisms underlying these
effects remain to be elucidated.
Herein, we analyzed some of the molecular mechanisms
through which euphol exerts its antiinﬂammatory action on
TPA-induced skin responses in mice. Data presented indicate that
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a consistent decline of TPA-induced skin inﬂammation as
assessed by skin edema and leukocyte inﬁltration. Likewise, we
observed an inhibitory effect of euphol on the activation of
downstream signaling proteins, namely PKC and MAPKs, which
in turn decreased the levels of CXC chemokines and
cyclooxygenase-2 (COX-2) following topical application of TPA.2. Materials and methods
2.1. Drugs and reagents
The following reagents were used: 12-O-tetradecanoylphorbol-
13-acetate (TPA), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic
acid (HEPES), phosphate buffered saline (PBS), trisodium citrate,
hydrogen peroxide, hematoxylin, MgCl2, KCl, NaCl, NaH2PO4,
Na2HPO4, phenylmethylsulphonyl ﬂuoride, ethylenediaminetetraa-
cetic acid (EDTA), paraformaldehyde, trypsin inhibitor, leupeptin,
pepstatin A, aprotinin, sodium orthovanadate, b-glycerophosphate,
sodium ﬂuoride, dithiothreitol, hexadecyl trimethyl ammonium
bromide, tetramethylbenzidine, 4-nitrophenyl N-acetyl-b-D-glucosa-
minide, Trizma base, Triton X-100, Tween 20, benzethonium chloride
(Sigma-Aldrich, S~ao Paulo, SP, Brazil), xylene, methanol, acetone,
ethanol, HCl (Merck & Co., Inc., Whitehouse Station, NJ, USA), anti-
p38, anti-extracellular signal-regulated protein kinase (ERK), anti-
PKCa, anti-PKCe, anti-PKCd (Santa Cruz Biotech. Inc., Santa Cruz, CA,
USA), anti-phosphorylated (p)-p38 (Thr180 and Tyr182), anti-p-ERK
(Thr183 and Tyr185) (Promega, Madison, WI, USA), anti-COX-2, and
3,30-diaminobenzidine (DAB) (Dako, Glostrup, Denmark).
The tetracyclic triterpene euphol was extracted from the sap of
E. tirucalli as previously described (Dutra et al., 2012). The purity
of the obtained compound was 498%.2.2. Animals
Experiments were conducted using 8-week-old male Swiss
CD-1 mice kept in a controlled room temperature (2272 1C) and
humidity (50–60%) under a 12 h light/dark cycle (lights on
6:00 A.M.). All procedures used in the present study followed
the ‘‘Principles of Laboratory Animal Care’’ from National Insti-
tutes of Health (NIH) publication number 85-23 and were
approved by the Animal Ethics Committee of the Universidade
Federal de Santa Catarina.2.3. TPA-induced skin inﬂammation and ear edema measurement
Skin inﬂammation was induced in the right ear by the topical
application of 2.5 mg/ear of TPA dissolved in 20 ml of acetone.
Control animals received the same volume of acetone (vehicle) in
the right ear. The ear edema was assessed at 2, 4, 6, 12 and 24 h
after TPA application and was expressed as the increase in ear
thickness due to the inﬂammatory challenge. Ear thickness was
measured before and after induction of the inﬂammatory
response by using a micrometer (Mitutoyo, Suzano, SP, Brazil)
that was applied near the tip of the ear just distal to the
cartilaginous ridges and the thickness was recorded in micro-
meter (mm). To minimize variation due to technique, a single
investigator performed the measurements throughout any one
experiment.
To evaluate the effect of euphol on TPA-induced skin inﬂam-
mation, animals were topically treated with euphol (50–100 mg/
ear) in conjunction with TPA. Control animals were treated with
vehicle (acetone/ethanol, 3:1).2.4. Myeloperoxidase and N-acetylglucosaminidase assays
Neutrophil and macrophage inﬁltration into the ear tissue was
assessed indirectly by measuring myeloperoxidase (MPO) and
N-acetylglucosaminidase (NAG) activities, respectively. The mea-
surements were carried out in 6 mm punch-biopsies obtained
from the mice ear 24 h after TPA-induced skin inﬂammation.
Tissues were homogenized at 5% (w/v) in EDTA/NaCl buffer (pH
4.7) and centrifuged at 10,000g for 15 min at 4 1C. The pellet was
resuspended in 0.5% hexadecyl trimethyl ammonium bromide
buffer (pH 5.4), and the samples were frozen in liquid nitrogen
and thawed three times. Upon thawing, the samples were
centrifuged as above, and 25 ml of the supernatant was used
for the MPO and NAG assays. The MPO enzymatic reaction was
assessed by addition of 1.6 mM tetramethylbenzidine, 80 mM
NaPO4, and 0.3 mM hydrogen peroxide. NAG activity measure-
ment was determined by adding 2.25 mM 4-nitrophenyl
N-acetyl-b-D-glucosaminide and 100 ml 50 mM citrate buffer
(pH 4.5). Absorbance was measured spectrophotometrically at
690 and 405 nm for MPO and NAG, respectively, and the results
are expressed as optical density (OD)/mg tissue.
2.5. Western blot
The western blot analyses were carried out in 6 mm punch-
biopsies obtained from the mice ear 2 h after TPA-induced skin
inﬂammation. Tissues were homogenized in ice-cold lysis buffer
[10 mM HEPES (pH 7.4), containing 1.5 mM MgCl2, 10 mM
KCl, 1 mM phenylmethylsulphonyl ﬂuoride, 5 mg/ml leupeptin,
7 mg/ml pepstatin A, 10 mg/ml aprotinin, 1.5 mg/ml trypsin inhi-
bitor, 2 mM sodium orthovanadate, 10 mM b-glycerophosphate,
50 mM sodium ﬂuoride, and 0.5 mM dithiothreitol]. The homo-
genates were chilled on ice for 15 min and then centrifuged at
12,000g for 60 min at 4 1C. The supernatant containing the
cytosolic fraction was collected and stored at 70 1C. The pellet
was resuspended in lysis buffer containing 1% Triton X-100,
homogenized and centrifuged at 12,000g for 30 min at 4 1C, and
the supernatant containing the membrane fraction was stored at
70 1C. Protein concentration was determined using the protein
assay kit according to the manufacturer’s instructions (Bio-Rad,
S~ao Paulo, SP, Brazil).
Equal protein amounts were separated on a sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then
transferred to a polyvynilidene ﬂuoride membrane (Immobilon P;
Millipore, Bedford, MA, USA). The membranes were blocked by
incubation with 10% non-fat dry milk solution and then incubated
overnight with antibodies against p38 (dilution 1:1000), ERK
(dilution 1:2000), (p)-p38 (Thr180 and Tyr182) (dilution 1:2000),
p-ERK(Thr183 and Tyr185) (dilution 1:5000), PKCa, PKCe, or PKCd
(dilution 1:1000). Following washing, the membranes were incu-
bated with the appropriate secondary antibodies coupled to
horseradish peroxidase. Immunocomplexes were visualized
with an enhanced chemiluminescence (ECL) detection kit
according to the manufacturer’s instructions (GE Healthcare,
S ~ao Paulo, SP, Brazil). Band density measurements were made
using the NIH ImageJ 1.36b imaging software (NIH, Bethesda,
MD, USA).
2.6. Determination of cytokine levels
Brieﬂy, 6 mm punch-biopsies obtained from the mice ear 24 h
after TPA-induced skin inﬂammation were homogenized in phos-
phate buffer containing 0.05% Tween 20, 0.1 mM phenylmethyl-
sulphonyl ﬂuoride, 0.1 mM benzethonium chloride, 10 mM EDTA,
and 20 IU aprotinin. The homogenate was centrifuged at 3000g
for 10 min, and supernatants were stored at 70 1C until further
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enzyme-linked immunosorbent assay (ELISA) kits from R&D
Systems (Minneapolis, MN, USA), according to the manufacturer’s
recommendations. Protein concentration was determined using
the protein assay kit according to the manufacturer’s instructions
(Bio-Rad, S~ao Paulo, SP, Brazil).
2.7. Assessment of protein kinase C activity
To assess PKC activity, ear samples were homogenized in ice-
cold lysis buffer [40 mM Tris-HCl (pH 7,5), 5 mM NaCl, 1 mM
MgCl2, 1 mM EDTA, 1 mM phenylmethylsulphonyl ﬂuoride,
10 mg/ml aprotinin, and 10 mg/ml leupeptin], and kept under
constant agitation for 45 min at 4 1C. The samples were then
centrifuged at 12,000g for 60 min at 4 1C, and the supernatant was
collected. Protein concentration was determined using the
protein assay kit according to the manufacturer’s instructions
(Bio-Rad, S~ao Paulo, SP, Brazil). PKC activity was analyzed using
an ELISA kit according to the manufacturer’s instructions (Calbio-
chem, Darmstadt, Germany).
2.8. Immunohistochemical studies
Ear samples were collected 24 h after TPA-induced skin inﬂam-
mation and ﬁxed in a PBS solution containing 4% paraformaldehyde
for 24 h at room temperature, dehydrated by graded ethanol, and
embedded in parafﬁn. Immunohistochemistry was carried out on
parafﬁn tissue sections (5 mm) using antibodies against vascular
endothelial growth factor (VEGF, dilution 1:300) or COX-2 (dilution
1:200). Following quenching of endogenous peroxidase with 1.5%
hydrogen peroxide in methanol (v/v) for 20 min, high temperature
antigen retrieval was performed by immersion of the slides in a
water bath at 95–98 1C in 10 mM trisodium citrate buffer pH 6.0,
for 45 min. The slides were then processed using the Vectastain
Elite ABC reagent according to the manufacturer’s instructions
(Vector Laboratories, Burlingame, CA, USA). Following the appro-
priate biotinylated secondary antibody, sections were developed
with DAB in chromogen solution and counterstained with Harris
hematoxylin. Control and experimental tissues were placed on the
same slide and processed in parallel.
Images of stained skin sections were acquired using a Sight
DS-5M-L1 digital camera connected to an Eclipse 50i light
microscope (both from Nikon, Melville, NY, USA). Six images
per section were captured, and a threshold optical density that
best discriminated staining from the background was obtained
using the ImageJ 1.36b imaging software. For burden analysis,
data were calculated as the labeled area captured (positive pixels)
divided by the full area captured (total pixels).Fig. 1. Effect of euphol on TPA-induced inﬂammation. Euphol was topically administ
animals were treated with vehicle (acetone/ethanol, 3:1). Ear edema (a) was measure
(c) activities were measured 24 h after TPA treatment. Each point represents the mean7
compared to vehicle/TPA-treated animals. O.D., optical density.2.9. Statistical analysis
The group Vehicle-Vehicle was considered as control. The
percentage of inhibition was calculated over the increase in the
response elicited by TPA in the vehicle group (the difference
between TPA-Vehicle and Vehicle-Vehicle was considered 100% of
response). For Fig. 5, inhibition was calculated as follows:
inhibition¼{1-([euphol-treated TPA]-[euphol-treated vehicle]/
[vehicle-treated TPA]-[vehicle-treated vehicle])}100. All the
results are presented as mean7standard error of the mean
(SEM). The statistical signiﬁcance between the groups was
assessed by means of one-way , two-way , or repeated-measures
ANOVA, followed by the Bonferroni’s post-hoc test. The accepted
level of signiﬁcance for the tests was Po0.05.3. Results
3.1. Effect of euphol on TPA-induced ear edema and cell inﬁltration
To examine the possible topical antiinﬂammatory effect of
euphol, mice were subjected to a single topical application of TPA
in the ear to model skin inﬂammation. Consistent with previous
reports, we observed a rapid onset and time-dependent edemato-
genic response in TPA-treated mice (Fig. 1a) (De Young et al., 1989).
The increase in ear edema was detected after 2 h of TPA treatment,
remaining signiﬁcantly elevated for at least 24 h. Notably, the topical
application of euphol (50–100 mg/ear) markedly inhibited the skin
inﬂammation induced by TPA, with both doses signiﬁcantly affecting
ear edema (Fig. 1a). Importantly, the 100 mg/ear dose inhibited the
edematogenic response for up to 24 h, and was used in the rest of the
experiments. The ear edema induced by TPA was inhibited by 37, 30,
24 and 47% at 4, 6, 12 and 24 h after euphol treatment (100 mg/ear),
in that order. In addition, the accumulation of polymorphonuclear
and mononuclear cells was also signiﬁcantly reduced by euphol
administration (Fig. 1b and c), as determined by MPO and NAG
assays, respectively. The MPO and NAG activities were inhibited by
15 and 42%, respectively, when assessed 24 h after treatment.
Administration of euphol to vehicle-treated mice was unable to
induce edema or cell inﬁltration in the mouse ear when compared to
control mice (vehicle/vehicle group; data not shown).
In accordance with the MPO assay, topical application of TPA
resulted in a signiﬁcant increase in the levels of the neutrophil
chemotactic chemokines CXCL1/KC and MIP-2 when evaluated
24 h after the treatment (Fig. 2). Notably, when mice were treated
with euphol (100 mg/ear), the TPA-induced upregulations of
CXCL1/KC and MIP-2 were inhibited by 38 and 17%, respectively
(Fig. 2A and B).ered (50–100 mg/ear, a; or 100 mg/ear, b and c) in conjunction with TPA. Control
d at 2, 4, 6, 12, and 24 h after TPA treatment (2.5 mg/ear), and MPO (b) and NAG
S.E.M. of 4–7 animals. **Po0.01 compared to vehicle-treated animals. ##Po0.01
Fig. 2. Euphol administration (100 mg/ear) inhibits TPA-induced chemokine upregulation. (A) CXCL1/KC, and (B) MIP-2 were measured 24 h after TPA treatment (2.5 mg/ear).
Each point represents the mean7S.E.M. of 4–5 animals. **Po0.01 compared to vehicle-treated animals. #Po0.05 and ##Po0.01 compared to vehicle/TPA-treated animals.
Fig. 3. Euphol administration (100 mg/ear) inhibits TPA-induced COX-2 up-regulation. (A) Representative images, and (B, C) graphic representation of COX-2 and VEGF
immunostaining in the mouse ear. Original magniﬁcation 400 . Immunohistochemical analysis was performed 24 h after TPA treatment (2.5 mg/ear). Each point
represents the mean7S.E.M. of 4–5 animals. **Po0.01 compared to vehicle-treated animals. ##Po0.01 compared to vehicle/TPA-treated animals.
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We and others have previously shown that TPA rapidly
stimulates COX-2 induction in the mouse skin (Medeiros et al.,
2007; Surh et al., 2002). Supporting this data, immunohistochem-
ical analysis revealed that topical application of TPA in the mouse
ear resulted in a dramatic (21-fold) upregulation of COX-2 in
comparison with vehicle-treated mice when evaluated 24 h after
treatment (Fig. 3A and B). In addition, the COX-2 upregulation
induced by TPA administration was signiﬁcantly inhibited (66%)in mice treated with euphol (100 mg/ear). On the other hand,
Fig. 3A and C indicate that euphol treatment was incapable of
affecting VEGF immunoreactivity in the ear at 24 h after TPA
administration.
3.3. Effect of euphol on TPA-induced activation of MAPKs
MAPKs are proteins that mediate the signal transduction from
the cell surface to the nucleus, and have been reported as
important regulators of inﬂammatory gene expression in mouse
Fig. 4. Effect of euphol (100 mg/ear) on TPA-induced MAPK activation. Western blot analysis of p-ERK (A) and p-p38 MAPK (B) activation was performed 24 h after TPA
administration (2.5 mg/ear). Quantiﬁcation of p-ERK and p-p38 MAPK was normalized by b-actin. Each point represents the mean7S.E.M. of 4–5 animals. *Po0.05 and
**Po0.01 compared to vehicle-treated animals. ##Po0.01 compared to vehicle/TPA-treated animals.
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indicate that very low levels of phosphorylated ERK and p38
MAPK are detected under basal conditions in the mouse ear.
Conversely, a marked activation of ERK (7-fold; Fig. 4A) and p38
MAPK (6-fold; Fig. 4B) was detected 24 h after the treatment. Of
interest, the topical treatment with euphol (100 mg/ear) signiﬁ-
cantly reduced the TPA-induced activation of ERK by 76%, but not
of p38 MAPK (Fig. 4A and B).
3.4. Inhibitory effect of euphol on TPA-induced PKC activation
Phorbol esters, such as TPA, are known to activate a series of
PKC iso-enzymes that mediate a strong inﬂammatory reaction
(Mueller, 2006). As expected, data shown in Fig. 5A indicate that
topical treatment with TPA resulted in a signiﬁcant increase in
PKC activity in comparison with vehicle-treated mice, when
evaluated 2 h after treatment (1.9-fold increase). Moreover, wes-
tern blot analysis demonstrated that PKCa, PKCd, and PKCe
isoforms were activated by TPA, as shown by increased transloca-
tion from cytosol- to membrane-rich fractions (Fig. 5B–D ).
Notably, the increase in PKC activity induced in the mouse ear
by TPA was signiﬁcantly inhibited by euphol treatment (100 mg/
ear) (inhibition of 74%; Fig. 5A). Western blot analysis revealed
that euphol prevented activation of PKCa and PKCd isoforms by
110 and 82%, respectively (Fig. 5B and C). Moreover, TPA-induced
PKCe activation was reduced 40% by euphol, although the effect
was not signiﬁcant (Fig. 5D). Of note, administration of euphol to
vehicle-treated mice was unable to change PKC activity when
compared to control mice (vehicle/vehicle group; Fig. 5).4. Discussion
In the current study, we demonstrated that topical adminis-
tration with tetracyclic triterpene euphol, isolated from the sap
from E. tirucalli, reduces cutaneous inﬂammation in mice follow-
ing exposure to the well-characterized protein kinase C activator
and tumor promoter TPA. Our data indicate that the mechanisms
underlying the antiinﬂamatory effect of euphol are associated
with its ability to prevent edema and leukocyte inﬁltration,
upregulation of COX-2 and chemokines, and activation of ERK,
PKCa and PKCd.
Chronic inﬂammation has been linked to many steps involved
in tumorigenesis, including transformation, promotion, survival,proliferation, invasion, angiogenesis, and metastasis (Aggarwal
et al., 2006). In fact, several clinical conditions associated with
inﬂammation appear to predispose the patient to increased
susceptibility for skin cancer including lupus erythematosus,
dystrophic epidermolysis bullosa, and chronic wound sites
(Nickoloff et al., 2005). These observations suggest that antiin-
ﬂammatory agents may have potential in prevention and treat-
ment of epithelial skin cancers. The topical administration of TPA
produces a long-lasting edematogenic response that is associated
with a marked inﬂux of mononuclear and polymorphonuclear
leukocytes (De Young et al., 1989; Rao et al., 1993). Importantly,
our data show that these events are signiﬁcantly inhibited by
euphol administration, as demonstrated by ear thickness, MPO
and NAG measurements. MPO is an enzyme found in the azur-
ophilic granules of neutrophils and other cells of myeloid origin,
and the utility of its measurement to correlate neutrophil inﬂux is
well established (Bradley et al., 1982). Likewise, NAG levels have
been used as an indicator of the presence of monocyte/macro-
phage cells in several inﬂammatory models (Rao et al.,
1993,1994). The recruitment of leukocytes to inﬂammatory sites
is a process largely orchestrated by small polypeptide cytokines
known as chemokines (Garin and Proudfoot, 2011). Recently, it
was demonstrated that TPA is capable of inducing the upregula-
tion of several chemokines, including the neutrophil chemokines
MIP-2 and CXCL1/KC (Cataisson et al., 2006). Corroborating these
data, we found signiﬁcantly increased levels of both chemokines
in TPA-treated ears, and topical application of euphol reduced
upregulation of MIP-2 and CXCL1/KC, indicating that inhibition of
MPO and NAG activities and leukocyte migration in response to
TPA may be related to the ability of euphol to inhibit chemokine
release.
It is now well recognized that upregulation of COX-2 plays an
important role in cancer and chronic inﬂammation (De Moraes
et al., 2007). While COX-2 is usually undetectable in most normal
adult tissues including skin, it is highly over expressed in a
number of different human cancers, as well as in several animal
models of carcinogenesis (Subbaramaiah and Dannenberg, 2003).
Importantly, COX-2-selective inhibitors exhibit chemopreventive
activity against chemical and ultraviolet light-induced skin carci-
nogenesis in mice (Chun et al., 2006; Orengo et al., 2002), with
genetic ablation of the enzyme resulting in a similar outcome
(Fischer et al., 2007; Tiano et al., 2002). In our study, we found a
signiﬁcant inhibitory effect of euphol against TPA-induced COX-2
expression in mouse skin, indicating that the inhibition of TPA-
Fig. 5. Effect of euphol (100 mg/ear) on TPA-induced PKC activation. (A) PKC activity on mouse ear protein extracts was analyzed by ELISA 2 h after TPA administration
(2.5 mg/ear). (B) PKCa, (C) PKCd, and (D) PKCe activation was conﬁrmed by western blot analysis of protein translocation from cytosol to membrane. The results represent
the ratio of membrane fraction protein detection over that of cytosolic fraction. Each point represents the mean7S.E.M. of 3–6 animals. *Po0.05 and **Po0.01 compared
to vehicle-treated animals. #Po0.05 and ##Po0.01 compared to vehicle/TPA-treated animals.
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COX-2 expression.
Next, we evaluated some of the intracellular pathways
involved in euphol antiinﬂammatory effects. The enzymes of the
MAP kinase family have been linked to the regulation COX-2
expression and other key proinﬂammatory genes, including
chemokines, and have become one of the most important targets
for drug development (Cohen, 2002). In the present study, we
demonstrated that topical treatment with euphol greatly inhib-
ited TPA-induced ERK, but not p38 MAPK activation. Of note,
several lines of evidence indicate that PKC plays an important role
in the activation of the ERK cascade in response to external
stimuli, including TPA (Lin et al., 2010).
Protein kinase C comprises a family of serine/threonine kinases
ﬁrst identiﬁed as intracellular receptors for tumor-promoting
phorbol esters, such as TPA (Kikkawa et al., 1983). These kinases
regulate a diverse set of cellular processes including proliferation,
apoptosis, cell survival and migration, and there is a substantial
amount of evidence linking PKC to tumorigenesis (Griner and
Kazanietz, 2007). Notably, PKC activation is signiﬁcantly reducedin mice treated with euphol, indicating that euphol effects result
from a direct action on PKC activity. At present, ten PKC isozymes
have been identiﬁed and classiﬁed in three subfamilies according
to the functional domain composition: conventional (cPKCs:
PKCa, PKCbI, PKCbII and PKCg), novel (nPKCs: PKCd, PKCe, PKCZ
and PKCy) and atypical (aPKCs: PKCz and PKCi) (Mackay and
Twelves, 2007). Conventional PKCs are regulated by diacylglycerol
(DAG), phosphatidylserine and calcium, whereas novel PKCs are
calcium-independent, but regulated by DAG and phosphatidylser-
ine, and atypical PKC isoforms are phosphatidylserine-dependent,
but calcium, DAG- and TPA-independent . Since only the former
two are activated by TPA, we analyzed the effect of euphol on
PKCa, PKCd, and PKCe activation, the isozymes expressed in
human (Fisher et al., 1993) and mouse epidermis (Wang et al.,
1993). Interestingly, our data demonstrated that the activation of
both PKCa and PKCd in response to TPA is markedly inhibited by
euphol. We also observed a reduction in PKCe activation, although
it was not signiﬁcant. Considerable evidence implicates PKCa in
the inﬂammatory response induced by TPA. Overexpression of
PKCa in mouse epidermis exacerbates TPA-induced inﬂammation
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matory proteins including TNF-a, COX-2 and chemokines, an
effect dependent on NF-kB activation (Cataisson et al., 2005;
Wang and Smart, 1999). Thus, the anti-inﬂammatory effect of
euphol in mouse skin can be related to the direct inhibition of
PKCa, resulting in reduced expression of COX-2, MIP-2 and
CXCL1/KC.
The isozymes of PKC family have been shown to exhibit distinct
roles in induction of skin cancer (Aziz et al., 2007). Notably, PKCd
and PKCe transgenic mice show different responses to skin tumor
promotion by TPA, with PKCe overexpressing transgenic mice
exhibiting enhanced carcinoma elicited by the two-step DMBA-
TPA protocol (Reddig et al., 2000), while increased expression of
PKCd in the mouse epidermis suppresses the formation of carcino-
mas (Reddig et al., 1999). Considering the opposing roles of PKCd
and PKCe in cancer, additional studies are necessary to further
characterize the effect of euphol in these isozymes.5. Conclusion
In the present data, we have provided in vivo evidence that the
plant-derived tetracyclic triterpene euphol exhibits strong topical
anti-inﬂammatory actions on mouse ear inﬂammation induced by
TPA, through a mechanism that involves its ability to regulate PKC
and ERK activation, resulting in reduced COX-2, MIP-2 and CXCL1/
KC upregulation and leukocyte inﬁltration. Taken together, our
data suggests that euphol may be a good candidate for the
treatment of skin disorders with an inﬂammatory component,
including cancer, although additional experiments using chronic
models need to be conducted to further establish the potential
efﬁcacy of euphol in these conditions.Acknowledgments
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